Select

Select

The purpose of this study is to demonstrate that semaglutide subcutaneously 2.4 mg once-weekly lowers the incidence of major adverse cardiovascular events in patients who are overweight or are obese and with prior cardiovascular disease.

Please use this link for further information:

Primary Investigator: Dean Kereiakes